Original Article
Comparison of Combination Therapy Which Has Incretin Action in Basal Insulin Therapy Using Continuous Glucose Monitor
Randomised Triple Crossover Study
2020 Volume 9 Issue 1 Pages 114-122
Details
2020 Volume 9 Issue 1 Pages 114-122
We investigated combinations of agents used together with basal insulin: vildagliptin 100mg (V)+metformin 500mg (M), V+miglitol 150mg (α) or M+α. Thirty type 2 diabetic patients were randomly allocated to three groups. On admission, Group 1: Patients took V+M (VM) and glucose level were stabilized by insulin glargine 300U/ml (Glargine300); next, patients wore a continuous glucose monitoring device (CGM) and then glycemic variability (GV) was evaluated on days 3 and 4; VM was switched to V+α (Vα) on day 5, and GV was evaluated on days 8 and 9; Vα was switched to M+α (Mα) on day 10 and GV was evaluated on days 13 and 14. Group 2: Patients took in the order of Vα, Mα, VM, following the same regimen. Group 3: Patients took in the order of, Mα, VM, Vα, following the same regimen. The same dose Glargine300 was injected during CGM measurement period. 24-h mean glucose level was significantly lower in patients on VM, Vα, Mα, in that order. VM is the most compatible combination to improve GV in basal insulin therapy.
